Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

New Technology Reduces Drug Development Costs

By BiotechDaily International staff writers
Posted on 04 Feb 2013
New technology based on cytochrome P450s (CYPs) proteins will speed up and reduce the cost of the development of new drugs and medicines.

The CYP super-family is a large and diverse group of enzymes that catalyze the oxidation of organic substances. The substrates of CYP enzymes include metabolic intermediates such as lipids and steroidal hormones, as well as xenobiotic substances such as drugs and other toxic chemicals. CYPs are the major enzymes involved in drug metabolism and bioactivation, accounting for about 75% of the total number of different metabolic reactions. The proteins are commercially available for use by companies involved in the discovery of new drugs, but are problematic as they must be transported and stored at temperatures as low as minus 80 degrees Celsius.

Researchers at De Montfort University (DMU; Leicester, United Kingdom) therefore developed a method that allows for CYPs to be shipped and handled at room temperature, eliminating the need for a cold chain, reducing costs, and making CYPs use in testing new drugs much quicker and easier. For the venture, DMU joined forces with life sciences commercialization company Ithaka Life Sciences (Ithaka, Cambridge, United Kingdom) to jointly establish a new company, which will be called CYP Design Limited (CDL, Cambridge, United Kingdom).

“The development of new drugs can be very time-consuming and costly. It can take up to 14 years from the initial idea and cost hundreds of millions of pounds. Thousands of potential new drugs are tested initially for every one successfully brought to market,” said Professor Bob Chaudhuri, PhD, who developed the new technology. “My group's development is designed to provide the proteins that are needed for this work in a cost effective and convenient format.”

“The technology that Professor Chaudhuri has been developing can have a significant impact on the timescales and costs involved in the early stages of drug discovery,” said Bill Primrose, PhD, CEO of CDL. “CYPs are currently transported on dry ice, at around minus 80 degrees Celsius, and are stored as cold as possible in the customer's laboratory until they are needed. His new technology eliminates the need for a cold chain, making it easier to manufacture and ship the proteins, and making them much more convenient for the customer to use.”

CYP-mediated transformations of drug candidates are of crucial importance in the pharmaceutical industry, with multiple roles. Oxidation by CYPs can lead to toxic products, but, on the other hand, local activation of anticancer drugs leads to lethal intracellular toxins at the site of the tumor. The metabolic clearance of most drugs depends on CYPs, and they have been implicated in a large number of drug interactions. Since drug interactions can result in fatalities, drug candidates with CYPs must be taken into account if the expensive and time-consuming development of active compounds with hidden toxic effects is to be avoided.

Related Links:

De Montfort University
Ithaka Life Sciences




comments powered by Disqus

Channels

Genomics/Proteomics

view channel

New Program Encourages Wide Distribution of Genomic Data

A new data sharing program allows genomics researchers and practitioners to analyze, visualize, and share raw sequence data for individual patients or across populations straight from a local browser. The sequencing revolution is providing the raw data required to identify the genetic variants underlying rare diseases... Read more

Drug Discovery

view channel
Image: The nano-cocoon drug delivery system is biocompatible, specifically targets cancer cells, can carry a large drug load, and releases the drugs very quickly once inside the cancer cell. Ligands on the surface of the \"cocoon\" trick cancer cells into consuming it. Enzymes (the “worms\" in this image) inside the cocoon are unleashed once inside the cell, destroying the cocoon and releasing anticancer drugs into the cell (Photo courtesy of Dr. Zhen Gu, North Carolina State University).

Novel Anticancer Drug Delivery System Utilizes DNA-Based Nanocapsules

A novel DNA-based drug delivery system minimizes damage to normal tissues by utilizing the acidic microenvironment inside cancer cells to trigger the directed release of the anticancer drug doxorubicin (DOX).... Read more

Lab Technologies

view channel

Experimental Physicists Find Clues into How Radiotherapy Kills Cancer Cells

A new discovery in experimental physics has implications for a better determination of the process in which radiotherapy destroys cancer cells. Dr. Jason Greenwood from Queen’s University Belfast (Ireland) Center for Plasma Physics collaborated with scientists from Italy and Spain on the work on electrons, and published... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.